Snowden Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Snowden Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-733	Closed	-$7.44K	–	1243
2024 Q4	$7.44K	Hold	733	–	–	﹤0.01%	1188
2024 Q3	$9.13K	Hold	733	–	–	﹤0.01%	1212
2024 Q2	$9.54K	Hold	733	–	–	﹤0.01%	1182
2024 Q1	$16.6K	Hold	733	–	–	﹤0.01%	1165
2023 Q4	$9.52K	Buy	+733	New	+$9.88K	﹤0.01%	1111
2023 Q3	–	Sell	-1,080	Closed	-$29K	–	1128
2023 Q2	$29K	Hold	1,080	–	–	﹤0.01%	1164
2023 Q1	$63K	Buy	1,080 +131	+14%	+$6.47K	﹤0.01%	1124
2022 Q4	$48.4K	Buy	949 +136	+17%	+$9.43K	﹤0.01%	1110
2022 Q3	$66K	Hold	813	–	–	﹤0.01%	1084
2022 Q2	$55K	Sell	813 -7	-0.9%	-$642	﹤0.01%	1094
2022 Q1	$90K	Buy	820 +547	+200%	+$68.2K	﹤0.01%	999
2021 Q4	$26K	Buy	+273	New	+$27.2K	﹤0.01%	1237

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Snowden Capital Advisors's KPTI Position: Q1 2025 in Review

Snowden Capital Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 733 shares — an estimated $7.44K sold.

Snowden Capital Advisors first reported a position in KPTI in Q4 2021 and held it in 12 quarters. The position peaked at $90K in Q1 2022. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

Snowden Capital Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
Snowden Capital Advisors sold 733 Karyopharm Therapeutics shares in Q1 2025, an estimated $7.44K.
Snowden Capital Advisors first reported a position in Karyopharm Therapeutics in Q4 2021 and held it in 12 quarters.
Snowden Capital Advisors's Karyopharm Therapeutics position peaked at $90K in Q1 2022.
49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Snowden Capital Advisors's 13F filing for Q1 2025, filed 14 May 2025.